TABLE 1.

Seroconversion rates and SARS‐CoV‐2 specific total antibody levels (indicated by antibody index) in individuals who received the Sinopharm/BBIBP‐CorV vaccine at 4 and 6 weeks

Age group	Seropositivity at 4 weeks N (%), 95% confidence interval	Antibody index (antibody titre) at 4 weeks median, IQR	Seropositivity at 6 weeks N (%)	Antibody index (antibody titre) at 6 weeks median, IQR
21–40 N = 89	54 (60.67%) (50.53%, 70.82%)	1.79 (0.58–4.48)	88 (98.88%) (96.69%, 100%)	13.22 (12.47–13.72
41–60 N = 163	82 (50.31%) (42.63%, 57.98%)	1.0 (0.13–3.85)	152 (93.25%) (89.40%, 97.10%)	12.6 (8.09–13.52)
>60 N = 30	19 (63.33%) (46.09%, 80.58%)	1.75 (0.55–4.77)	28 (93.33%) (84.41%, 100%)	12.42 (5.41–13.52)